Alumis Inc. (ALMS) Announces Phase 2b Topline Results for Envudeucitinib

What Happened
Alumis Inc. (ALMS) announced on September 1, 2026 the topline results from the LUMUS Phase 2b trial of envudeucitinib in systemic lupus erythematosus (SLE). The company filed a press release and the presentation slides from a webcast as Exhibits 99.1 and 99.2 to its Form 8-K. The presentation is described as summary information and is incorporated by reference into the filing.

Key Details

• Date filed: September 1, 2026 (Form 8-K, Item 8.01 — Other Events).
• Documents filed: Press release (Exhibit 99.1) and LUMUS Phase 2b topline results presentation (Exhibit 99.2).
• Regulatory plan disclosed: Alumis states plans to submit a New Drug Application (NDA) for envudeucitinib in Q4 2026.
• Pipeline notes: Company highlighted potential for envudeucitinib across interferon-driven diseases (e.g., cutaneous lupus, Sjögren’s) and referenced development of A-005 for neuroinflammatory/neurodegenerative diseases including Parkinson’s.

Why It Matters
Topline Phase 2b results and a stated plan to submit an NDA in Q4 2026 are material developments for investors: they can affect the company’s regulatory timeline, perceived clinical progress, and the valuation of Alumis’ TYK2-focused portfolio. The filing also reiterates forward-looking statements and associated risks (e.g., regulatory acceptance, safety/efficacy outcomes, and future trial replication), so investors should review the full press release, presentation, and the company’s SEC filings for detail before drawing conclusions.